Ind-Swift Laboratories
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Ind-Swift Laboratories is strategically transitioning to a formulation-focused entity, emphasizing higher-margin chronic-therapy drugs and complex formulations. Management's dual strategy of leveraging domestic stability while expanding globally is crucial for revenue growth and margin improvement. The company's focus on upgrading manufacturing to meet stringent EU-GMP standards and optimizing distribution channels supports Vista's forecast of stable revenue growth and improving margins. Despite a favorable industry backdrop, including increasing demand for Indian CDMOs and improving pricing power, challenges such as raw material shortages and geopolitical risks remain pertinent. Over the next 12-24 months, key opportunities include expanding into Latin America and enhancing operational efficiency, while watchpoints include the execution of capacity expansions and input cost inflation. Vista's outlook reflects a fair valuation with an expected upside of 22.15%, aligning with management's targets for FY27 and beyond
Why We Like This Stock
- Management's focus on higher-margin chronic-therapy drugs enhances revenue potential
- Strategic expansion into regulated markets and facility upgrades support margin improvement
- Strong balance sheet and disciplined capital allocation position the company for sustainable growth
Things To Watch Out For
- Raw material shortages and geopolitical instability pose risks to operational execution
- Dependence on high-volume US generic formulations may limit growth in a competitive landscape
- Potential delays in capacity expansions could hinder revenue targets
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,281 | 562 | 641 | 753 | 811 |
| Profit Before Tax (Cr.) | 193 | 6 | 60 | 92 | 93 |
| PBT Margin | 15.1% | 1.1% | 9.4% | 12.2% | 11.5% |
| Net Profit (Cr.) | 130 | 0 | 44 | 68 | 69 |
| Earnings Per Share | 15.0 | 0.1 | 5.1 | 7.8 | 7.9 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.